Mikhail E. Diatroptov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mikhail E. Diatroptov has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology
18 shared publications - Olga Vasilievna Makarova
Petrovsky National Research Centre of Surgery, Moscow 117418, Russia
10 shared publications - Tatiana Valentinovna Popkova
Nasonova Research Institute of Rheumatology
10 shared publications - Dzhuliia Dzhalilova
Avtsyn Research Institute of Human Morphology, Petrovsky National Research Center of Surgery, Moscow, Russia
9 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
9 shared publications - Yu. N. Gorbunova
V.A. Nasonova Research Institute of Rheumatology
9 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 513-522
Dynamics of cytokine profile parameters during olokizumab therapy: Results of a single-center randomized controlled trial
The aim – to evaluate the effect of olokizumab (OKZ) on the levels of proand anti-inflammatory cytokines, chemokines, and growth factors in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included; 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents (BAs). At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio into one of three groups: Group 1 received treatment with sDMARDs+OKZ 64 mg subcutaneously once every 4 weeks (4N) (n=49); Group 2 – sDMARDs+OKZ 64 mg subcutaneously 4N + psychopharmacotherapy (PPT) (n=51); Group 3 – sDMARDs+PPT (n=25). The study duration was 24 weeks. The concentration of 27 cytokines in the serum was measured using multiplex xMAP technology on a Bio-Plex array system analyzer (Bio-Rad, USA). Results . After 12 weeks of OKZ therapy, a significant decrease in the level of proinflammatory cytokines – interleukin (IL) 2; anti-inflammatory cytokines – IL-4, IL-10, IL-13, IL-1 receptor antagonist (IL-1Ra); chemokines – macrophage inflammatory protein 1α (MIP-1α), interferon γ-stimulated protein 10 (IP-10), IL-8; growth factors – IL-7, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF-bb); an increase in the level of anti-inflammatory cytokines – IL-5, IL-9, Eotaxin and tumor necrosis factor α (TNF-α); after 24 weeks of therapy – a decrease in the level of pro-inflammatory cytokines – IL-2, IL-15; anti-inflammatory cytokines – IL-4, IL-13, IL-1Ra; chemokines – monocyte chemotactic protein-1 (MCP-1), MIP-1α, IL-8; growth factors – IL-7, PDGF-bb; increased levels of Eotaxin and TNF-α. Conclusion. The use of OKZ is accompanied by a decrease in the level of proinflammatory cytokines, chemokines, and growth factors, and an increase in the content of TNF-α.
- 31 October 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 513-522
Open AccessDynamics of cytokine profile parameters during olokizumab therapy: Results of a single-center randomized controlled trial
The aim – to evaluate the effect of olokizumab (OKZ) on the levels of proand anti-inflammatory cytokines, chemokines, and growth factors in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included; 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents (BAs). At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio into one of three groups: Group 1 received treatment with sDMARDs+OKZ 64 mg subcutaneously once every 4 weeks (4N) (n=49); Group 2 – sDMARDs+OKZ 64 mg subcutaneously 4N + psychopharmacotherapy (PPT) (n=51); Group 3 – sDMARDs+PPT (n=25). The study duration was 24 weeks. The concentration of 27 cytokines in the serum was measured using multiplex xMAP technology on a Bio-Plex array system analyzer (Bio-Rad, USA). Results . After 12 weeks of OKZ therapy, a significant decrease in the level of proinflammatory cytokines – interleukin (IL) 2; anti-inflammatory cytokines – IL-4, IL-10, IL-13, IL-1 receptor antagonist (IL-1Ra); chemokines – macrophage inflammatory protein 1α (MIP-1α), interferon γ-stimulated protein 10 (IP-10), IL-8; growth factors – IL-7, fibroblast growth factor (FGF), platelet-derived growth factor (PDGF-bb); an increase in the level of anti-inflammatory cytokines – IL-5, IL-9, Eotaxin and tumor necrosis factor α (TNF-α); after 24 weeks of therapy – a decrease in the level of pro-inflammatory cytokines – IL-2, IL-15; anti-inflammatory cytokines – IL-4, IL-13, IL-1Ra; chemokines – monocyte chemotactic protein-1 (MCP-1), MIP-1α, IL-8; growth factors – IL-7, PDGF-bb; increased levels of Eotaxin and TNF-α. Conclusion. The use of OKZ is accompanied by a decrease in the level of proinflammatory cytokines, chemokines, and growth factors, and an increase in the content of TNF-α.
- Open Access
- 30 August 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (4) , 415-421
Asymptomatic myocardial dysfunction and cytokines in patients with systemic lupus erythematosus
Background. Systemic lupus erythematosus (SLE) is associated with a high risk of early cardiovascular disease, which is driven by chronic systemic inflammation associated with proinflammatory cytokines and autoantibodies. Heart failure is 2–4 times more common in patients with SLE than in the general population, and mortality is twice as high. The aim of the study – to assess the incidence of asymptomatic myocardial dysfunction (AMD) in patients with systemic lupus erythematosus before the administration of genetic engineering therapy and to analyze its association with clinical and immunological characteristics and cytokine levels. Materials and methods . We included 100 patients with SLE according to the 2012 SLICC (Systemic Lupus International Collaborating Clinics) criteria (age 36±11 years) and 38 healthy controls, matched for gender and age. SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) activity was 8 [6; 13] points. Ninetyfive percent received glucocorticoids, and 84% received hydroxychloroquine. Thirty-nine patients were diagnosed with hypertension, coronary heart disease (CHD) in 1, and stroke in 1. Echocardiography was performed to assess global longitudinal myocardial strain (GLS) of the left (LV) and right ventricles (RV). Levels of interleukin (IL) 6, IL-1 receptor antagonist (IL-1RA), IL-18, and tumor necrosis factor α (TNF-α) were determined in the blood serum. Results. SLE patients had lower LV GLS and RV GLS values than in the control group (–18.6 [–19.8; –16.5]% vs –20.3 [–21.5; –19.6]%; –19.2 [–22.8; –16.1]% vs –21.9 [–23.5; –21.2]%, respectively; pConclusion . SLE patients are highly likely to have impaired LV and RV GPD, as well as elevated levels of IL-1RA, IL-6, IL-18, and TNF-α. ADM is associated with SLE activity, clinical manifestations, and elevated cytokine levels (IL-18, IL-1RA), confirming the role of chronic inflammation in the development of SDM.
- 30 August 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (4) , 415-421
Open AccessAsymptomatic myocardial dysfunction and cytokines in patients with systemic lupus erythematosus
Background. Systemic lupus erythematosus (SLE) is associated with a high risk of early cardiovascular disease, which is driven by chronic systemic inflammation associated with proinflammatory cytokines and autoantibodies. Heart failure is 2–4 times more common in patients with SLE than in the general population, and mortality is twice as high. The aim of the study – to assess the incidence of asymptomatic myocardial dysfunction (AMD) in patients with systemic lupus erythematosus before the administration of genetic engineering therapy and to analyze its association with clinical and immunological characteristics and cytokine levels. Materials and methods . We included 100 patients with SLE according to the 2012 SLICC (Systemic Lupus International Collaborating Clinics) criteria (age 36±11 years) and 38 healthy controls, matched for gender and age. SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) activity was 8 [6; 13] points. Ninetyfive percent received glucocorticoids, and 84% received hydroxychloroquine. Thirty-nine patients were diagnosed with hypertension, coronary heart disease (CHD) in 1, and stroke in 1. Echocardiography was performed to assess global longitudinal myocardial strain (GLS) of the left (LV) and right ventricles (RV). Levels of interleukin (IL) 6, IL-1 receptor antagonist (IL-1RA), IL-18, and tumor necrosis factor α (TNF-α) were determined in the blood serum. Results. SLE patients had lower LV GLS and RV GLS values than in the control group (–18.6 [–19.8; –16.5]% vs –20.3 [–21.5; –19.6]%; –19.2 [–22.8; –16.1]% vs –21.9 [–23.5; –21.2]%, respectively; pConclusion . SLE patients are highly likely to have impaired LV and RV GPD, as well as elevated levels of IL-1RA, IL-6, IL-18, and TNF-α. ADM is associated with SLE activity, clinical manifestations, and elevated cytokine levels (IL-18, IL-1RA), confirming the role of chronic inflammation in the development of SDM.
- Open Access
- 27 August 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (10) , 584-589
Hepcidin, but not erythropoietin, levels are associated with decreased testosterone in men with immune-mediated inflammatory rheumatic diseases and anemia
Background. Anemia and decreased testosterone levels in men are common comorbidities in immune-mediated inflammatory rheumatic diseases (IIRDs). Aim. To evaluate the relationship between total testosterone (TT) and hepcidin and erythropoietin levels in men with IIRDs and anemia. Materials and methods. A cross-sectional study included 136 men with IIRDs (66 patients with rheumatoid arthritis – RA, 44 with ankylosing spondylitis – AS, 26 with psoriatic arthritis – PsA) and anemia. A correlation analysis was performed for all quantitative parameters with TT, hepcidin, and erythropoietin levels, as well as a comparative subgroup analysis between patients with normal and reduced (≤12.0 nmol/L) TT. Results. In RA, AS and PsA and anemia, the subgroup with reduced TT was characterized by comparable levels of hemoglobin and erythropoietin compared to patients without androgen deficiency. The hepcidin level in RA patients with testosterone deficiency was significantly higher (38.0 [31.8; 39.1] ng/ml versus 21.5 [7.8; 30.5] ng/ml; p0.001) in RA patients. Among patients with AS, the subgroup with reduced TT was characterized by comparable levels of hepcidin (29.2 [6.5; 34.1] ng/ml versus 31.3 [27.2; 34.9] ng/ml; p=0.3). Among patients with PsA, the subgroup with reduced TT levels was characterized by higher hepcidin levels in testosterone deficiency (37.0 [29.9; 38.7] ng/ml vs. 25.8 [4.6; 33.0] ng/ml; p=0.009). Conclusion. The obtained results indicate no relationship between TT levels and erythropoietin in patients with RA, AS, and PsA and concomitant anemia, while reduced TT levels were associated with increased hepcidin levels in RA and PsA, and are most likely due to high IIRD activity.
- 27 August 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (10) , 584-589
Open AccessHepcidin, but not erythropoietin, levels are associated with decreased testosterone in men with immune-mediated inflammatory rheumatic diseases and anemia
Background. Anemia and decreased testosterone levels in men are common comorbidities in immune-mediated inflammatory rheumatic diseases (IIRDs). Aim. To evaluate the relationship between total testosterone (TT) and hepcidin and erythropoietin levels in men with IIRDs and anemia. Materials and methods. A cross-sectional study included 136 men with IIRDs (66 patients with rheumatoid arthritis – RA, 44 with ankylosing spondylitis – AS, 26 with psoriatic arthritis – PsA) and anemia. A correlation analysis was performed for all quantitative parameters with TT, hepcidin, and erythropoietin levels, as well as a comparative subgroup analysis between patients with normal and reduced (≤12.0 nmol/L) TT. Results. In RA, AS and PsA and anemia, the subgroup with reduced TT was characterized by comparable levels of hemoglobin and erythropoietin compared to patients without androgen deficiency. The hepcidin level in RA patients with testosterone deficiency was significantly higher (38.0 [31.8; 39.1] ng/ml versus 21.5 [7.8; 30.5] ng/ml; p0.001) in RA patients. Among patients with AS, the subgroup with reduced TT was characterized by comparable levels of hepcidin (29.2 [6.5; 34.1] ng/ml versus 31.3 [27.2; 34.9] ng/ml; p=0.3). Among patients with PsA, the subgroup with reduced TT levels was characterized by higher hepcidin levels in testosterone deficiency (37.0 [29.9; 38.7] ng/ml vs. 25.8 [4.6; 33.0] ng/ml; p=0.009). Conclusion. The obtained results indicate no relationship between TT levels and erythropoietin in patients with RA, AS, and PsA and concomitant anemia, while reduced TT levels were associated with increased hepcidin levels in RA and PsA, and are most likely due to high IIRD activity.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 67-74
Prospective study of the effect of a glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation parameters in patients with knee osteoarthritis (report 2)
Objective: to evaluate the effect of a combination of glucosamine hydrochloride (GH) 500 mg and chondroitin sulfate (CS) 500 mg on systemic inflammation parameters in patients with inflammatory (IP) and metabolic (MP) phenotypes of knee osteoarthritis (OA). Material and methods. At the first stage of the study, which lasted 3 months, the efficacy of Artra® was evaluated in 70 patients with a definite diagnosis of stage II–III knee OA and walking pain ≥4 points on the numerical rating scale (NRS). All patients received Artra® and topical nonsteroidal anti-inflammatory drugs as needed. Changes in NRS pain, the WOMAC index, and patient global health assessment using a visual analog scale were determined. At the second stage of the study, the efficacy of Artra® was analyzed in two patient subgroups: those with the metabolic phenotype of OA (n=29) and those with the inflammatory phenotype of OA (n=12). CRP levels were measured in all patients at visits 1 and 3; in 22 patients, serum concentrations of 17 cytokines, chemokines, and growth factors were also measured at baseline and after 3 months. Results and discussion . After a 3-month course of therapy, a statistically significant (pConclusion . Artra® is characterized by a significant symptomatic effect, including analgesic and anti-inflammatory effects, in patients with the OA phenotypes that are most difficult to treat, namely MP and IP. Our study confirmed the ability of the drug to reduce the production of several proinflammatory cytokines and chemokines that play an important role in the development and progression not only of OA but also of other agerelated diseases, including metabolic syndrome. The findings indicate that the drug can affect different components of OA pathogenesis, which supports its use in patients with comorbidities.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 67-74
Open AccessProspective study of the effect of a glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation parameters in patients with knee osteoarthritis (report 2)
Objective: to evaluate the effect of a combination of glucosamine hydrochloride (GH) 500 mg and chondroitin sulfate (CS) 500 mg on systemic inflammation parameters in patients with inflammatory (IP) and metabolic (MP) phenotypes of knee osteoarthritis (OA). Material and methods. At the first stage of the study, which lasted 3 months, the efficacy of Artra® was evaluated in 70 patients with a definite diagnosis of stage II–III knee OA and walking pain ≥4 points on the numerical rating scale (NRS). All patients received Artra® and topical nonsteroidal anti-inflammatory drugs as needed. Changes in NRS pain, the WOMAC index, and patient global health assessment using a visual analog scale were determined. At the second stage of the study, the efficacy of Artra® was analyzed in two patient subgroups: those with the metabolic phenotype of OA (n=29) and those with the inflammatory phenotype of OA (n=12). CRP levels were measured in all patients at visits 1 and 3; in 22 patients, serum concentrations of 17 cytokines, chemokines, and growth factors were also measured at baseline and after 3 months. Results and discussion . After a 3-month course of therapy, a statistically significant (pConclusion . Artra® is characterized by a significant symptomatic effect, including analgesic and anti-inflammatory effects, in patients with the OA phenotypes that are most difficult to treat, namely MP and IP. Our study confirmed the ability of the drug to reduce the production of several proinflammatory cytokines and chemokines that play an important role in the development and progression not only of OA but also of other agerelated diseases, including metabolic syndrome. The findings indicate that the drug can affect different components of OA pathogenesis, which supports its use in patients with comorbidities.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
Features of the cytokine profile of patients with systemic lupus erythematosus depending on the presence of an interferon signature
The aim – to evaluate the cytokine profile of patients with systemic lupus erythematosus (SLE) depending on the presence of increased expression of interferon (IFN) stimulated genes. Materials and methods. The analysis included 140 patients (123 (88%) women and 17 (12%) men) with a confirmed diagnosis of SLE. Disease duration was 3.0 [0.3; 12.0] years, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) score was 6.5 [4.0; 10.5] points, SDI (Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index) – 0 [0; 2] points. IFN status was assessed by the expression of IFN-stimulated genes (MX1, RSAD2, EPSTI1) using real-time polymerase chain reaction. A study of 48 serum cytokines was performed using a multiplex immunoassay based on xMAP suspension microarray technology (BioPlex® 200 Pro Human Cytokine Screening Panel, 48-Plex, Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. The control group consisted of 13 healthy donors matched for gender and age. Results. Expression of IFN-stimulated genes and the IFN score were significantly higher in patients with SLE compared to healthy donors ( p < 0.05). The IFN signature was present in 103 (81.7%) patients and absent in 23 (18.3%) patients. Patients with the IFN signature had higher levels of proinflammatory cytokines (tumor necrosis factor α (TNF-α), interleukin (IL) 18, TRAIL (TNF-related apoptosis-inducing ligand)), chemokines (IP-10 (interferon gamma-induced protein 10)), growth factors (macrophage colony-stimulating factor (M-CSF), anti-inflammatory cytokines (IL-1 receptor antagonist (IL-1Ra)), and lower levels of hepatocyte growth factor. Conclusion . The immunological phenotype with the IFN signature is characterized by higher levels of proinflammatory cytokines (TNF-α, IL-18, TRAIL), chemokines (IP-10), growth factors (M-CSF), and anti-inflammatory cytokines (IL-1Ra), which suggests higher inflammatory activity in this group of patients.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
Features of the cytokine profile of patients with systemic lupus erythematosus depending on the presence of an interferon signature
The aim – to evaluate the cytokine profile of patients with systemic lupus erythematosus (SLE) depending on the presence of increased expression of interferon (IFN) stimulated genes. Materials and methods. The analysis included 140 patients (123 (88%) women and 17 (12%) men) with a confirmed diagnosis of SLE. Disease duration was 3.0 [0.3; 12.0] years, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) score was 6.5 [4.0; 10.5] points, SDI (Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index) – 0 [0; 2] points. IFN status was assessed by the expression of IFN-stimulated genes (MX1, RSAD2, EPSTI1) using real-time polymerase chain reaction. A study of 48 serum cytokines was performed using a multiplex immunoassay based on xMAP suspension microarray technology (BioPlex® 200 Pro Human Cytokine Screening Panel, 48-Plex, Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. The control group consisted of 13 healthy donors matched for gender and age. Results. Expression of IFN-stimulated genes and the IFN score were significantly higher in patients with SLE compared to healthy donors ( p < 0.05). The IFN signature was present in 103 (81.7%) patients and absent in 23 (18.3%) patients. Patients with the IFN signature had higher levels of proinflammatory cytokines (tumor necrosis factor α (TNF-α), interleukin (IL) 18, TRAIL (TNF-related apoptosis-inducing ligand)), chemokines (IP-10 (interferon gamma-induced protein 10)), growth factors (macrophage colony-stimulating factor (M-CSF), anti-inflammatory cytokines (IL-1 receptor antagonist (IL-1Ra)), and lower levels of hepatocyte growth factor. Conclusion . The immunological phenotype with the IFN signature is characterized by higher levels of proinflammatory cytokines (TNF-α, IL-18, TRAIL), chemokines (IP-10), growth factors (M-CSF), and anti-inflammatory cytokines (IL-1Ra), which suggests higher inflammatory activity in this group of patients.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
The clinical significance of antibodies to ribosomal protein P (a-Rib-P) in patients with systemic lupus erythematosus and antiphospholipid syndrome
The aim – to determine the clinical significance of hyperproduction of antibodies to ribosomal protein P (a-Rib-P) in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Material and methods . The study included 68 patients with reliable diagnoses of SLE and APS (SLE – 25, SLE+APS – 19, primary APS (PAPS) – 24). Young (35,1±10,2 years) women prevailed (72,1%). All patients were examined according to the standards recommended by the Association of Rheumatologists of Russia, and also examined by a psychiatrist. a-Rib-P was determined in all patients and 20 healthy donors, matched by gender and age, by enzyme immunoassay in blood serum. Results . The concentration of a-Rib-P in patients was significantly higher than in healthy donors (0.004 [0.003; 0.015] vs 0.002 [0.002; 0.003] U/ml, respectively; p =0.002). Elevated a-Rib-P values were detected in 6 (13.6%) out of 44 patients with SLE, but were not detected in PAPS and in healthy donors. In patients with current neurological disorders (stroke/epilepsy/hyperkinesis), the concentration of a-Rib-P is statistically significantly higher than in their absence (0.004 [0.003; 0.021] vs 0.002 [0.002; 0.003] U/ml, respectively; p =0.001). The concentration of a-Rib-P is significantly higher in patients with SLE and elevated values of antibodies to double stranded DNA/anti-Smith antibodies (a-Sm), compared with those with normal values of these autoantibodies (0.005 [0.004; 0.106] vs 0.004 [0.002; 1.35], respectively; p =0.007 and 2.41 [0.058; 10.3] vs 0.005 [0.002; 0.012] U/ml, respectively; p=0.001). Patients with an increased a-Rib-P value had a significantly higher chance of skin (odds ratio (OR) – 17.0; p Conclusion . a-Rib-P are highly specific for patients with SLE and aren’t typical for patients with PAPS. They are associated with various clinical and laboratory manifestations of high SLE activity, primarily skin-mucosal, neurological, and immunological.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
The clinical significance of antibodies to ribosomal protein P (a-Rib-P) in patients with systemic lupus erythematosus and antiphospholipid syndrome
The aim – to determine the clinical significance of hyperproduction of antibodies to ribosomal protein P (a-Rib-P) in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Material and methods . The study included 68 patients with reliable diagnoses of SLE and APS (SLE – 25, SLE+APS – 19, primary APS (PAPS) – 24). Young (35,1±10,2 years) women prevailed (72,1%). All patients were examined according to the standards recommended by the Association of Rheumatologists of Russia, and also examined by a psychiatrist. a-Rib-P was determined in all patients and 20 healthy donors, matched by gender and age, by enzyme immunoassay in blood serum. Results . The concentration of a-Rib-P in patients was significantly higher than in healthy donors (0.004 [0.003; 0.015] vs 0.002 [0.002; 0.003] U/ml, respectively; p =0.002). Elevated a-Rib-P values were detected in 6 (13.6%) out of 44 patients with SLE, but were not detected in PAPS and in healthy donors. In patients with current neurological disorders (stroke/epilepsy/hyperkinesis), the concentration of a-Rib-P is statistically significantly higher than in their absence (0.004 [0.003; 0.021] vs 0.002 [0.002; 0.003] U/ml, respectively; p =0.001). The concentration of a-Rib-P is significantly higher in patients with SLE and elevated values of antibodies to double stranded DNA/anti-Smith antibodies (a-Sm), compared with those with normal values of these autoantibodies (0.005 [0.004; 0.106] vs 0.004 [0.002; 1.35], respectively; p =0.007 and 2.41 [0.058; 10.3] vs 0.005 [0.002; 0.012] U/ml, respectively; p=0.001). Patients with an increased a-Rib-P value had a significantly higher chance of skin (odds ratio (OR) – 17.0; p Conclusion . a-Rib-P are highly specific for patients with SLE and aren’t typical for patients with PAPS. They are associated with various clinical and laboratory manifestations of high SLE activity, primarily skin-mucosal, neurological, and immunological.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
Galectins-1, -3, -9 and type I interferon signature in systemic lupus erythematosus: Is there a relationship?
The aim of the study – to clarify the relationship between serum levels of galectins-1, -3, and -9 and type I interferon gene signature (IFNGS) and to compare its potential as biomarkers of “positive” interferon status in patients with systemic lupus erythematosus (SLE). Material and methods . The cross-sectional study included 60 women and 11 men with a diagnosis of SLE established according to the SLICC (Systemic Lupus International Collaborating Clinics) 2012 criteria. The patients’ age was 33 [25; 43] years, and the median duration of the disease was 30 [2; 132] months. 19 (26.8 %) patients had high and very high SLE activity (SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) >10), and 24 (33.8%) had moderate activity (SLEDAI-2K=5–10). Glucocorticoids were received by 58 (81.7%), hydroxychloroquine – by 57 (80.3%), immunosuppressants – by 28 (39.4%) patients. The control group included 20 people without immunoinflammatory rheumatic diseases. IFNGS were evaluated by the expression of interferoninduced genes ( MX1, RSAD2, EPSTI1 ) using real-time polymerase chain reaction. If the average indicated genes expression in the patient exceeded that in the control group, IFNGS was considered “positive”, if not – “negative”. Galectin-1, -3 and -9 levels were determined in the blood serum of SLE patients by the enzyme-linked immunosorbent assay (reagents by Cloud-Clone Corp., China). Results . “Positive” IFNGS was detected in 53 (74.6%) of 71 patients with SLE. The galectin-1 and galectin-3 concentrations were comparable in patients with “positive” and “negative” IFNGS, while the level of galectin-9 was higher in patients with gene overexpression (0.009 [0.002; 0.69] vs 0.002 [0.001; 0.003] pg/ml, respectively; p =0.02). A weak correlation was found between serum galectin-9 levels and EPSTI1 gene expression ( r =0.26; p =0.03). In the ROC analysis of using galectin-9 levels as a marker of “positive” IFNGS, the area under the curve was 0.682 (95% confidence interval: 0.537–0.827; p =0.021), and the cutoff point was 0.0025 pg/ml (sensitivity 71.7%, specificity 72.2%). Conclusion . In SLE patients, serum concentrations of galectin-9, but not galectin-1 and galectin-3, were associated with overexpression of type I interferon-induced genes, namely, EPSTI1 . ROC-analysis demonstrated the average quality of the model in the case of using galectin-9 as the only serological biomarker of “positive” IFNGS in SLE. Further research is needed to clarify the diagnostic value of the combination of galectin-9 with other proteins whose synthesis depends on type I interferon.
- 30 June 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (3)
Galectins-1, -3, -9 and type I interferon signature in systemic lupus erythematosus: Is there a relationship?
The aim of the study – to clarify the relationship between serum levels of galectins-1, -3, and -9 and type I interferon gene signature (IFNGS) and to compare its potential as biomarkers of “positive” interferon status in patients with systemic lupus erythematosus (SLE). Material and methods . The cross-sectional study included 60 women and 11 men with a diagnosis of SLE established according to the SLICC (Systemic Lupus International Collaborating Clinics) 2012 criteria. The patients’ age was 33 [25; 43] years, and the median duration of the disease was 30 [2; 132] months. 19 (26.8 %) patients had high and very high SLE activity (SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) >10), and 24 (33.8%) had moderate activity (SLEDAI-2K=5–10). Glucocorticoids were received by 58 (81.7%), hydroxychloroquine – by 57 (80.3%), immunosuppressants – by 28 (39.4%) patients. The control group included 20 people without immunoinflammatory rheumatic diseases. IFNGS were evaluated by the expression of interferoninduced genes ( MX1, RSAD2, EPSTI1 ) using real-time polymerase chain reaction. If the average indicated genes expression in the patient exceeded that in the control group, IFNGS was considered “positive”, if not – “negative”. Galectin-1, -3 and -9 levels were determined in the blood serum of SLE patients by the enzyme-linked immunosorbent assay (reagents by Cloud-Clone Corp., China). Results . “Positive” IFNGS was detected in 53 (74.6%) of 71 patients with SLE. The galectin-1 and galectin-3 concentrations were comparable in patients with “positive” and “negative” IFNGS, while the level of galectin-9 was higher in patients with gene overexpression (0.009 [0.002; 0.69] vs 0.002 [0.001; 0.003] pg/ml, respectively; p =0.02). A weak correlation was found between serum galectin-9 levels and EPSTI1 gene expression ( r =0.26; p =0.03). In the ROC analysis of using galectin-9 levels as a marker of “positive” IFNGS, the area under the curve was 0.682 (95% confidence interval: 0.537–0.827; p =0.021), and the cutoff point was 0.0025 pg/ml (sensitivity 71.7%, specificity 72.2%). Conclusion . In SLE patients, serum concentrations of galectin-9, but not galectin-1 and galectin-3, were associated with overexpression of type I interferon-induced genes, namely, EPSTI1 . ROC-analysis demonstrated the average quality of the model in the case of using galectin-9 as the only serological biomarker of “positive” IFNGS in SLE. Further research is needed to clarify the diagnostic value of the combination of galectin-9 with other proteins whose synthesis depends on type I interferon.
- 30 April 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Dynamics of inflammatory markers and interleukin 6 levels during olokizumab therapy: Results of a single-center randomized controlled trial
The aim – to evaluate the effect of olokizumab (OKZ) on acute-phase reactants, interleukin (IL) 6, and its soluble receptor (sIL-6R) levels in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included, including 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents. At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio to one of three groups: Group 1 received treatment with sDMARDs + OKZ 64 mg subcutaneously once every 4 weeks (n=49); group 2 – sDMARDs + OKZ 64 mg subcutaneously + psychopharmacotherapy (PPT) (n=51); group 3 – sDMARDs + PFT (n=25). The study duration was 24 weeks. Serum IL-6 concentrations were determined using xMAP multiplex technology on a Bio-Plex Array System analyzer (Bio-Rad, USA) and immunochemiluminescence assay (ICL) on a Cobas e411 analyzer (Roche, Switzerland). Results. The use of OKZ was accompanied by a significant decrease in the level of C-reactive protein (CRP) and calprotectin (CP) in the group as a whole; normalization of the CRP level was noted 4 weeks after the start of therapy (pConclusion . Thus, the use of OKZ is accompanied by a decrease in the levels of acute-phase reactants, CP, IL-6, and sIL-6R. CP can be considered a more sensitive marker for assessing inflammation during OKZ therapy compared to CRP.
- 30 April 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Dynamics of inflammatory markers and interleukin 6 levels during olokizumab therapy: Results of a single-center randomized controlled trial
The aim – to evaluate the effect of olokizumab (OKZ) on acute-phase reactants, interleukin (IL) 6, and its soluble receptor (sIL-6R) levels in patients with rheumatoid arthritis (RA) and comorbid depression. Material and methods . A total of 125 patients with RA and comorbid depression were included, including 102 (81.6%) women, with a mean age of 48.5±12.6 years. The majority (86.4%) had high RA activity and had failed stable 12-week therapy with synthetic disease-modifying antirheumatic drugs (DMARDs). Thirty-four (27.2%) patients had failed one or more biological agents. At week 0, all patients were randomized using the sequential numbers method in a 2:2:1 ratio to one of three groups: Group 1 received treatment with sDMARDs + OKZ 64 mg subcutaneously once every 4 weeks (n=49); group 2 – sDMARDs + OKZ 64 mg subcutaneously + psychopharmacotherapy (PPT) (n=51); group 3 – sDMARDs + PFT (n=25). The study duration was 24 weeks. Serum IL-6 concentrations were determined using xMAP multiplex technology on a Bio-Plex Array System analyzer (Bio-Rad, USA) and immunochemiluminescence assay (ICL) on a Cobas e411 analyzer (Roche, Switzerland). Results. The use of OKZ was accompanied by a significant decrease in the level of C-reactive protein (CRP) and calprotectin (CP) in the group as a whole; normalization of the CRP level was noted 4 weeks after the start of therapy (pConclusion . Thus, the use of OKZ is accompanied by a decrease in the levels of acute-phase reactants, CP, IL-6, and sIL-6R. CP can be considered a more sensitive marker for assessing inflammation during OKZ therapy compared to CRP.
- 1 January 2026
- Published by Publishing House RAMS in Bulletin of Experimental Biology and Medicine
- Vol. 181 (2)
The correlation between rhythmic changes in body temperature and large-scale fluctuations in atmospheric pressure in the 10–30-minute range of periods
Исследована динамика температуры тела в дневной период у самцов расписного перепела (Synoicus chinensis) в сопоставлении с флуктуациями атмосферного давления. Атмосферное давление измерялось тремя датчиками, расположенными в углах равностороннего треугольника с длиной стороны 18–20 км. Исследуемые животные находились в центре этого треугольника, где был расположен четвёртый датчик давления. Показана связь динамики температуры тела только с теми колебаниями атмосферного давления, которые регистрировались одновременно на всех датчиках. Данный факт указывает на связь ультрадианной ритмики температуры тела перепелов в 10–30-минутном диапазоне периодов не с непосредственным влиянием атмосферного давления, а с фактором, который генерируется при его крупномасштабных флуктуациях, или же этот биотропный фактор сам является причиной наблюдаемых крупномасштабных флуктуаций атмосферного давления. Также показано, что фаза этих ультрадианных ритмов зависит от местного солнечного времени, что указывает на их внешнюю обусловленность, возможно, движением солнечного терминатора.
- 1 January 2026
- Published by Publishing House RAMS in Bulletin of Experimental Biology and Medicine
- Vol. 181 (2)
The correlation between rhythmic changes in body temperature and large-scale fluctuations in atmospheric pressure in the 10–30-minute range of periods
Исследована динамика температуры тела в дневной период у самцов расписного перепела (Synoicus chinensis) в сопоставлении с флуктуациями атмосферного давления. Атмосферное давление измерялось тремя датчиками, расположенными в углах равностороннего треугольника с длиной стороны 18–20 км. Исследуемые животные находились в центре этого треугольника, где был расположен четвёртый датчик давления. Показана связь динамики температуры тела только с теми колебаниями атмосферного давления, которые регистрировались одновременно на всех датчиках. Данный факт указывает на связь ультрадианной ритмики температуры тела перепелов в 10–30-минутном диапазоне периодов не с непосредственным влиянием атмосферного давления, а с фактором, который генерируется при его крупномасштабных флуктуациях, или же этот биотропный фактор сам является причиной наблюдаемых крупномасштабных флуктуаций атмосферного давления. Также показано, что фаза этих ультрадианных ритмов зависит от местного солнечного времени, что указывает на их внешнюю обусловленность, возможно, движением солнечного терминатора.